DBVT News and Press, DBV Technologies S.A. From 03/17/20

                      Monthly information regarding the total number of voting rights and  total number of shares of the Company as of February 29, 2020 and March 4, 2020 (Article 223-16 of the General Regulations of the ...

Gainers:  Sundance Energy (NASDAQ: SNDE ) +320% . More news on: Sundance Energy, Inc., BioNTech SE, Jiayin Group Inc., Stocks on the move, , Read more ...

DBV Technologies (NASDAQ: DBVT )  -50%  on hiccup with Viaskin Peanut . More news on: DBV Technologies S.A., GNC Holdings, Inc., Sasol Limited, Stocks on the move, , Read more ...

DBV Technologies (NASDAQ: DBVT ) craters  45%  premarket on increased volume in reaction to its announcement that the FDA, during its review of its marketing application for Viaskin Peanut, has identified "questions" about efficacy, including the impact of patch-site adhesion. ...

Montrouge, France, March 16, 2020 DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years                    Conference call today, March 16, at 5:00 PM ET / 10:00 PM C...

Montrouge, France, February 24, 2020 DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced ...

Montrouge, France, February 21, 2020 DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Montrouge, France, February 10, 2020 DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that...

Aimmune Therapeutics Inc (NASDAQ: AIMT) -- a California-based biotechnology company -- recently made history. The company's drug Palforzia became the first treatment for peanut allergies to be approved by the U.S. Food and Drug Administration (FDA). Naturally, investors received the news w...

Monthly information regarding the total number of voting rights and  total number of shares of the Company as of January 31, 2020 and February 4, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Pari...